Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Dr Nadeem on Efficacy and Safety of Arlo-Cel for R/R Myeloma

September 19th 2025, 9:10pm

International Myeloma Society Annual Meeting

Omar Nadeem, MD, discusses updated data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr Rodriguez-Otero on Data for Linvoseltamab in High-Risk Smoldering Myeloma

September 19th 2025, 8:41pm

International Myeloma Society Annual Meeting

Paula Rodriguez-Otero, MD, discusses safety and efficacy findings with linvoseltamab, a bispecific antibody targeting BCMA, in patients with high-risk smoldering multiple myeloma.

Belantamab Mafodotin Triplet Yields Responses With Low Ocular Toxicity in Intermediate-Fit or Frail Newly Diagnosed Myeloma

September 19th 2025, 8:38pm

International Myeloma Society Annual Meeting

Belantamab mafodotin plus lenalidomide and dexamethasone induced CRs or better in over half of patients with newly diagnosed multiple myeloma.

Co-Infusion of Anti-GPRC5D/Anti-BCMA Therapies Is Feasible, Yields Durable Responses in R/R Multiple Myeloma

September 19th 2025, 7:10pm

International Myeloma Society Annual Meeting

Administering the anti-GPRC5D agent MCARH109 and anti-BCMA therapy MCARH125 in tandem was feasible and tolerable in relapsed/refractory multiple myeloma.

Eque-Cel Demonstrates Activity in R/R Multiple Myeloma

September 19th 2025, 5:30pm

International Myeloma Society Annual Meeting

Eque-cel was effective for the treatment of patients with relapsed/refractory multiple myeloma.

Arlo-Cel Demonstrates Tolerability, Efficacy in R/R Myeloma

September 19th 2025, 4:30pm

International Myeloma Society Annual Meeting

Arlo-cel given as a single infusion drove efficacy and was safe in relapsed/refractory multiple myeloma.

D-VRd Produces Favorable PROs and Safety Outcomes in MRD-Negative Newly Diagnosed Multiple Myeloma

September 19th 2025, 3:56pm

International Myeloma Society Annual Meeting

D-VRd led to favorable PRO outcomes in patients with newly diagnosed multiple myeloma who had MRD negativity after therapy.

Maintenance Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Produces Responses in High-Risk Myeloma

September 19th 2025, 3:24pm

International Myeloma Society Annual Meeting

Maintenance therapy with belantamab mafodotin, pomalidomide, and dexamethasone was safe and led to durable responses in high-risk myeloma.

Iberdomide/Daratumumab/Dexamethasone Is Effective in Newly Diagnosed Multiple Myeloma

September 18th 2025, 11:35pm

International Myeloma Society Annual Meeting

Iberdomide plus daratumumab and dexamethasone yielded deep responses and had a manageable safety profile in transplant-ineligible multiple myeloma.

Dr Weinberg on the Rationale for Combining BXCL701 With Pembrolizumab in mPDAC

September 18th 2025, 11:05pm

ESMO Gastrointestinal Cancers Congress

Benjamin A. Weinberg, MD, discusses the rationale for examining BXCL701 plus pembrolizumab in mPDAC.

Fixed-Duration Cevostamab After CAR T-Cell Therapy Is Well Tolerated in Heavily Pretreated Myeloma

September 18th 2025, 9:19pm

International Myeloma Society Annual Meeting

Data from a phase 2 study suggested that fixed-duration cevostamab is both feasible and safe in patients with heavily pretreated multiple myeloma.

Dr San Miguel on the Association Between MRD-Negative CR and PFS/Safety in Newly Diagnosed Myeloma

September 18th 2025, 8:11pm

International Myeloma Society Annual Meeting

Jesús San Miguel, MD, PhD, discusses patient-reported outcomes and safety for patients with newly diagnosed multiple myeloma who achieved MRD negativity and a CR or better.

Linvoseltamab Plus Carfilzomib Is Safe, Feasible, and Elicits Durable Responses in R/R Myeloma

September 18th 2025, 7:31pm

International Myeloma Society Annual Meeting

Linvoseltamab plus carfilzomib produced expected toxicities in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Catamero on Challenges of Community-Based Administration of Bispecifics and CAR T-Cell Therapy in Myeloma

September 18th 2025, 7:26pm

International Myeloma Society Annual Meeting

Donna Catamero, ANP-BC, OCN, CCRC, discusses the challenges community-based clinicians face in delivering bispecific antibodies and CAR T-cell therapy for multiple myeloma.

Isa-KRd Leads to MRD Negativity in Subgroups of High-Risk Newly Diagnosed Multiple Myeloma

September 18th 2025, 4:04pm

International Myeloma Society Annual Meeting

Isa-KRd led to a 74.8% MRD negativity rate in high-risk newly diagnosed multiple myeloma subgroups.

SHR-4849 Shows Preliminary Activity With Manageable Safety in Relapsed Small Cell Lung Cancer

September 18th 2025, 12:00pm

IASLC World Conference on Lung Cancer

SHR-4849 showed acceptable safety and early antitumor activity in relapsed small cell lung cancer.

SHR-4849 Shows Activity With Manageable Safety in Relapsed Small Cell Lung Cancer

September 18th 2025, 12:00pm

IASLC World Conference on Lung Cancer

SHR-4849 showed acceptable safety and preliminary antitumor activity in relapsed small cell lung cancer.

Dr Mouhieddine on the Potential Predictive Role of Ferritin Levels and ALC in Bispecific Antibody–Treated Multiple Myeloma

September 17th 2025, 11:42pm

International Myeloma Society Annual Meeting

Tarek Mouhieddine, MD, discusses the predictive role of ferritin levels and ALC in patients with multiple myeloma receiving bispecific antibodies.

ISB 2001 Shows Favorable Safety Profile and Antitumor Activity in R/R Multiple Myeloma

September 17th 2025, 11:16pm

International Myeloma Society Annual Meeting

ISB 2001 had a manageable safety profile and induced deep, durable responses at active doses in patients with relapsed/refractory multiple myeloma.

Dr Raab on Updated Findings With Teclistamab-Based Induction in Newly Diagnosed Multiple Myeloma

September 17th 2025, 9:01pm

International Myeloma Society Annual Meeting

Marc S. Raab, MD, PhD, discusses the efficacy of teclistamab-based induction in patients with newly diagnosed multiple myeloma.